Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018046803) COMBINING ADENOVIRUS AND CHECKPOINT INHIBITORS FOR TREATING CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/046803 International Application No.: PCT/FI2017/050645
Publication Date: 15.03.2018 International Filing Date: 11.09.2017
IPC:
C07K 16/28 (2006.01) ,A61K 35/761 (2015.01) ,C07K 14/535 (2006.01) ,A61K 39/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
[IPC code unknown for A61K 35/761]
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
53
Colony-stimulating factor (CSF)
535
Granulocyte CSF; Granulocyte-macrophage CSF
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
TARGOVAX OY [FI/FI]; Saukonpaadenranta 2 FI-00180 Helsinki, FI
Inventors:
RANKI, Tuuli; FI
PESONEN, Sari; FI
JÄDERBERG, Magnus; GB
HAAVISTO, Elina; FI
KURYK, Lukasz; FI
VUOLANTO, Antti; FI
Agent:
BOCO IP OY AB; Itämerenkatu 5 00180 Helsinki, FI
Priority Data:
16188301.212.09.2016EP
Title (EN) COMBINING ADENOVIRUS AND CHECKPOINT INHIBITORS FOR TREATING CANCER
(FR) COMBINAISON ADÉNOVIRUS ET INHIBITEURS DE POINTS DE CONTRÔLE POUR LE TRAITEMENT DU CANCER
Abstract:
(EN) The invention relates to the combination therapy comprising oncolytic adenovirus vector and a checkpoint inhibitor or checkpoint inhibitors. More specifically, the invention relates to oncolytic adenovirus vector and checkpoint inhibitor or checkpoint inhibitors for use in a cancer therapy.
(FR) L'invention concerne la polythérapie comprenant un vecteur d'adénovirus oncolytique et un inhibiteur de point de contrôle ou des inhibiteurs de points de contrôle. Plus précisément, l'invention concerne un vecteur d'adénovirus oncolytique et un inhibiteur de point de contrôle ou des inhibiteurs de points de contrôle pour une utilisation dans une cancérothérapie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)